News - UCB

Filter

Current filters:

UCB

Popular Filters

36 to 60 of 65 results

UCB reports 5% lift in first nine-month sales

29-10-2012

Belgium's largest pharma company, UCB (UCB: BR), has reported interim results for the first nine months…

FinancialLicensingolokizumabPharmaceuticalUCB

Belgium's UCB enters third research accord with Harvard University

10-10-2012

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB), says it has launched a third collaborative…

ImmunologicalsPharmaceuticalResearchUCB

Belgium's UCB granted EIB financing for CNS R&D program

28-09-2012

The European Investment Bank (EIB) will grant financing to UCB (Euronext Brussels: UCB), Belgium's largest…

EuropeFinancialNeurologicalPharmaceuticalResearchUCB

UCB inaugurates new biotech plant

16-09-2012

In preparation for the growing demand for biological medicines, Belgian drugmaker UCB (Euronext Brussels:…

BiotechnologyEuropePharmaceuticalProductionUCB

Positive Ph IV data for Pfizer and UCB's Toviaz

06-08-2012

Global drugs behemoth Pfizer (NYSE: PFE) has released positive Phase IV study results assessing the efficacy…

Genito-urinaryPfizerPharmaceuticalResearchToviazUCB

UCB first-half 2012 results miss expectations, hit by costs

02-08-2012

Belgian drugmaker UCB posted first-half 2012 financial results, showing that underlying profitability…

FinancialPharmaceuticalUCB

UCB's Neupro re-launched in USA for Parkinson's and RSL

16-07-2012

Belgium drugmaker UCB (Euronext Brussels: UCB) said yesterday that its Neupro (rotigotine transdermal…

Markets & MarketingNeuproNeurologicalNorth AmericaPharmaceuticalUCB

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

UCB's Vimpat effective in achieving seizure control in patients with refractory epilepsy

08-07-2012

Results published in the June online edition of Seizure from an independent multicenter study covering…

NeurologicalPharmaceuticalResearchUCBVimpat

UCB buys majority stake in local drugmaker to expand in Brazil

31-05-2012

Belgium's leading pharma company UCB (Euronext Brussels: UCB) says it has signed an agreement to acquire…

GenericsMeizler BiopharmaMergers & AcquisitionsPharmaceuticalSouth AmericaUCB

UCB debuts two major projects for epilepsy in UK

21-05-2012

The UK subsidiary of Belgian drugmaker UCB (Euronext Brussels: UCB) yesterday announced two new projects…

NeurologicalPharmaceuticalResearchUCB

FDA approves UCB drug Neupro for PD and RLS

03-04-2012

Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that the US Food and Drug Administration…

NeuproNeurologicalNorth AmericaPharmaceuticalRegulationUCB

UCB links with Oxford University for research

19-03-2012

he UK subsidiary of Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that it has agreed…

PharmaceuticalResearchUCB

UCB and Domainex elaborate on cancer drug target collaboration

12-03-2012

Belgian drugmaker UCB (Euronext Brussels: UCB) and Domainex, a UK-based drug discovery company, have…

BiotechnologyDomainexOncologyPharmaceuticalResearchUCB

UCB sees strong showing from core products in 2011

05-03-2012

Belgian drugmaker UCB (UCB: BR) announced consolidated 2011 financial results, showing that revenue increased…

FinancialPharmaceuticalUCB

Opportunities for Pharma in narcolepsy

20-02-2012

The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

UCB links with Astellas for Cimzia in Japan

02-02-2012

Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Mylan debuts innovative version of levetiracetam

19-01-2012

US generic drugmaker Mylan (Nasdaq: MYL) says that its Mylan Institutional business has launched Levetiracetam…

GenericsKeppraLevetiracetamMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaUCB

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

UCB and Immunomedics amend epratuzumab accord

29-12-2011

New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

UCB pulls out of Biotie partnership on SYN118

25-11-2011

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that, as it had already expected following disappointing…

Biotie TherapiesLicensingNeurologicalPharmaceuticalUCB

UCB adds to CNS portfolio with acquisition of Lectus’ key pharmaceutical assets

23-11-2011

Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held,…

Lectus TherapeuticsMergers & AcquisitionsNeurologicalPharmaceuticalResearchUCB

36 to 60 of 65 results

Company Spotlight

Fibrotech

Fibrotech

Back to top